Tesla’s ‘American-made’ cars won’t get hit as hard by the auto tariffs

WASHINGTON, March 27 (Reuters) – The U.S. Congressional Budget Office on Thursday projected significant increases in federal budget deficits and debt over the next 30 years, in part due to rapidly rising interest costs, as it sketched out sluggish economic growth and a shrinking workforce.
The CBO’s latest long-term budget projections show federal deficits accelerating to 7.3% of the economy in fiscal year 2055 from 6.2% in 2025. That is up from the 30-year average from 1995 to 2024 of 3.9%.
Core consumer inflation in Japan’s capital stayed above the central bank’s target and accelerated in March on steady gains in food costs, data showed on Friday, keeping alive market expectations of a near-term interest rate hike.
Service-sector inflation also perked up as rent prices rose ahead of the April start of Japan’s new fiscal year, backing up the Bank of Japan’s view that price pressures were broadening.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.
The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial investments in research and development to create innovative, patent-protected drugs. Successful products can generate significant revenue streams over their patent life, and the larger a roster of drugs, the stronger a moat a company enjoys. However, the business model is inherently risky, with high failure rates during clinical trials, lengthy regulatory approval processes, and intense competition from generic and biosimilar manufacturers once patents expire. These challenges, combined with scrutiny over drug pricing, create a complex operating environment. Looking ahead, the industry is positioned for tailwinds from advancements in precision medicine, increasing adoption of AI to enhance drug development efficiency, and growing global demand for treatments addressing chronic and rare diseases. However, headwinds include heightened regulatory scrutiny, pricing pressures from governments and insurers, and the looming patent cliffs for key blockbuster drugs. Patent cliffs bring about competition from generics, forcing branded pharmaceutical companies back to the drawing board to find the next big thing.
The 11 branded pharmaceuticals stocks we track reported a mixed Q4. As a group, revenues beat analysts’ consensus estimates by 1.3%.
While some branded pharmaceuticals stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 1.4% since the latest earnings results.
With roots dating back to 1849 when two German immigrants opened a fine chemicals business in Brooklyn, Pfizer (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a wide range of diseases and conditions.
Pfizer reported revenues of $17.76 billion, up 21.9% year on year. This print exceeded analysts’ expectations by 3%. Overall, it was a strong quarter for the company with a solid beat of analysts’ organic revenue and EPS estimates.
The stock is down 3.8% since reporting and currently trades at $25.22.
Is now the time to buy Pfizer? Access our full analysis of the earnings results here, it’s free.
With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson’s disease, and migraine.
Supernus Pharmaceuticals reported revenues of $174.2 million, up 6% year on year, outperforming analysts’ expectations by 12.2%. The business had a very strong quarter with an impressive beat of analysts’ EPS estimates and full-year operating income guidance topping analysts’ expectations.
Supernus Pharmaceuticals scored the biggest analyst estimates beat among its peers. However, the results were likely priced into the stock as it’s traded sideways since reporting. Shares currently sit at $32.79.
Is now the time to buy Supernus Pharmaceuticals? Access our full analysis of the earnings results here, it’s free.
Originally spun off from Pfizer in 2013 as the world’s largest pure-play animal health company, Zoetis (NYSE:ZTS) discovers, develops, and sells medicines, vaccines, diagnostic products, and services for pets and livestock animals worldwide.
Zoetis reported revenues of $2.32 billion, up 4.7% year on year, in line with analysts’ expectations. It was a softer quarter as it posted a significant miss of analysts’ full-year EPS guidance estimates.
As expected, the stock is down 7.1% since the results and currently trades at $161.61.
Read our full analysis of Zoetis’s results here.
With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE:BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases.
Bristol-Myers Squibb reported revenues of $12.34 billion, up 7.5% year on year. This print surpassed analysts’ expectations by 6.6%. Zooming out, it was a mixed quarter as it also produced an impressive beat of analysts’ EPS estimates but a significant miss of analysts’ full-year EPS guidance estimates.
The stock is flat since reporting and currently trades at $59.20.
Spun off from Merck in 2021 to create a company dedicated to addressing unmet needs in women’s health, Organon (NYSE:OGN) is a global healthcare company focused on improving women’s health through prescription therapies, medical devices, biosimilars, and established medicines.
Organon reported revenues of $1.59 billion, flat year on year. This number topped analysts’ expectations by 0.9%. However, it was a slower quarter as it logged full-year revenue guidance missing analysts’ expectations significantly.
IT distribution giant TD SYNNEX (NYSE:SNX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 4% year on year to $14.53 billion. Next quarter’s revenue guidance of $14.3 billion underwhelmed, coming in 2.7% below analysts’ estimates. Its non-GAAP profit of $2.80 per share was 3.6% below analysts’ consensus estimates.
Revenue: $14.53 billion vs analyst estimates of $14.79 billion (4% year-on-year growth, 1.7% miss)
Adjusted EPS: $2.80 vs analyst expectations of $2.91 (3.6% miss)
Adjusted EBITDA: $427.1 million vs analyst estimates of $435.3 million (2.9% margin, 1.9% miss)
Revenue Guidance for Q2 CY2025 is $14.3 billion at the midpoint, below analyst estimates of $14.7 billion
Adjusted EPS guidance for Q2 CY2025 is $2.70 at the midpoint, below analyst estimates of $3.03
Operating Margin: 2.1%, in line with the same quarter last year
Free Cash Flow was -$789.5 million, down from $343.6 million in the same quarter last year
Market Capitalization: $10.58 billion
“The strength of our business model allowed us to grow ahead of the market in Q1. Our end-to-end strategy, global reach and specialist go to market approach continues to empower us to capture a wide range of IT spend,” said Patrick Zammit, CEO of TD SYNNEX.
Serving as the crucial middleman in the technology supply chain, TD SYNNEX (NYSE:SNX) is a global technology distributor that connects thousands of IT manufacturers with resellers, helping businesses access hardware, software, and technology solutions.
IT Distribution & Solutions will be buoyed by the increasing complexity of IT ecosystems, rising cloud adoption, and demand for cybersecurity solutions. Enterprises are less likely than ever to embark on these complicated journeys solo, and companies in the sector boast expertise and scale in these areas. However, cloud migration also means less need for hardware, which could dent demand for large portions of the product portfolio and hurt margins. Additionally, planning for potentially supply chain disruptions is ongoing, as the COVID-19 pandemic showed how damaging a pause in global trade could be in areas like semiconductor procurement.
Examining a company’s long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years.
With $59.01 billion in revenue over the past 12 months, TD SYNNEX is a behemoth in the business services sector and benefits from economies of scale, giving it an edge in distribution. This also enables it to gain more leverage on its fixed costs than smaller competitors and the flexibility to offer lower prices.
As you can see below, TD SYNNEX’s sales grew at an incredible 21.2% compounded annual growth rate over the last five years. This shows it had high demand, a useful starting point for our analysis.
We at StockStory place the most emphasis on long-term growth, but within business services, a half-decade historical view may miss recent innovations or disruptive industry trends. TD SYNNEX’s recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 2.4% over the last two years.
This quarter, TD SYNNEX’s revenue grew by 4% year on year to $14.53 billion, falling short of Wall Street’s estimates. Company management is currently guiding for a 2.5% year-on-year increase in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 5.9% over the next 12 months, an improvement versus the last two years. This projection is above the sector average and implies its newer products and services will spur better top-line performance.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories.
Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes.
TD SYNNEX was profitable over the last five years but held back by its large cost base. Its average operating margin of 1.9% was weak for a business services business.
Analyzing the trend in its profitability, TD SYNNEX’s operating margin might fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.
This quarter, TD SYNNEX generated an operating profit margin of 2.1%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
TD SYNNEX’s flat EPS over the last five years was below its 21.2% annualized revenue growth. However, its operating margin didn’t change during this time, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings.
We can take a deeper look into TD SYNNEX’s earnings to better understand the drivers of its performance. A five-year view shows TD SYNNEX has diluted its shareholders, growing its share count by 63.9%. This has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q1, TD SYNNEX reported EPS at $2.80, down from $2.99 in the same quarter last year. This print missed analysts’ estimates. Over the next 12 months, Wall Street expects TD SYNNEX’s full-year EPS of $11.48 to grow 15.9%.
We struggled to find many positives in these results. Its revenue guidance for next quarter missed significantly and its EPS guidance for next quarter fell short of Wall Street’s estimates. Overall, this was a softer quarter. The stock traded down 9.7% to $113.32 immediately after reporting.